Ionis Pharmaceuticals
IONS
332 hedge funds and large institutions have $4.62B invested in Ionis Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 107 increasing their positions, 109 reducing their positions, and 50 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
23% more capital invested
Capital invested by funds: $3.75B → $4.62B (+$875M)
0.94% more ownership
Funds ownership: 87.27% → 88.21% (+0.94%)
2% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 109
6% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 50
2% less funds holding
Funds holding: 340 → 332 (-8)
44% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $20.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TBC
Tweedy, Browne Co
Stamford,
Connecticut
|
+$95.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$60.9M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$52.7M |
| 4 |
ClearBridge Investments
New York
|
+$19.4M |
| 5 |
Goldman Sachs
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$46.9M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$29.8M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$18.3M |
| 4 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$14.7M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$14.3M |
IONS Hedge Fund Activity: Q1 2022 in Review
332 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2022, worth a combined $4.62B — up 23% from $3.75B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of IONS and 47 opened new positions — a net loss of 3 holders — while 109 trimmed existing stakes and 107 added.
The largest buyer was Tweedy, Browne Co, opening a new position worth an estimated $95.7M. The largest seller was Millennium Management, cutting an estimated $46.9M.
- 332 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2022, down from 340 in Q4 2021.
- Funds reported $4.62B of Ionis Pharmaceuticals stock for Q1 2022, up 23% quarter-over-quarter.
- 47 funds opened new Ionis Pharmaceuticals positions in Q1 2022 and 50 closed out, a net change of -3 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2022 was Tweedy, Browne Co, an estimated $95.7M added.
- The largest Ionis Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $46.9M sold.
Based on aggregated 13F filings for Q1 2022.